REDWOOD CITY, CA--(Marketwire - August 19, 2008) - PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) will hold an investor conference call and webcast today at 5:00 p.m. Eastern time following today's announcement of a collaboration agreement with Bristol-Myers Squibb Company for the co-development and commercialization of elotuzumab, PDL's phase 1 antibody candidate for multiple myeloma, and an option, exercisable by Bristol-Myers Squibb, to expand the collaboration to include PDL241, a preclinical antibody candidate for immunologic indications. The company plans to discuss this collaboration as well as provide an update on company activities.
